-
Basel, November 23, 2022 — As the threat of resistance to current malaria treatments grows1,2, Novartis and MMV announce the decision to progress ganaplacide/lumefantrine- solid dispersion formulation (SDF) into Phase 3 development for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.MalariaChildren's HealthAfricaAccess to Healthcare
-
Basel, June 23, 2022 — Novartis endorses the Kigali Declaration on neglected tropical diseases (NTDs) and announces a five-year financial commitment of USD 250 million to the fight against NTDs and malaria in conjunction with the Kigali Summit on Malaria and NTDs alongside the 26th Commonwealth Heads of Government (CHOGM) meeting. This summit…MalariaInfectious DiseasesFuture of HealthcareAfricaAccess to Healthcare
-
Thierry Diagana and his team are on a quest to discover new therapeutics for malaria. He believes malaria elimination is within our grasp, but emerging drug resistance could jeopardize the hard-fought progress.
Access to HealthcareInfectious DiseasesMalariaMedical InnovationsTropical Diseases -
Chronic IllnessEnvironmental SustainabilityInfectious DiseasesMalariaNovartis Institutes for BioMedical Research
-
Basel, September 29, 2021 — As the threat of resistance to current malaria treatment grows, Novartis and MMV have reported positive results of a new non-artemisinin combination in a Phase 2b study.MalariaAfrica
-
The digital press release with multimedia content can be accessed here:MalariaDisease EradicationAfrica
-
The Hague, the Netherlands; Geneva and Basel, Switzerland, March 3, 2020. The European & Developing Countries Clinical Trials Partnership (EDCTP) awarded a new grant to the new PAMAfrica research consortium led by Medicines for Malaria Venture (MMV). The consortium will support the development of new treatments for malaria in the most-at-…MalariaAfricaAccess to Healthcare
-
In a medical treatment facility on the Thai-Burmese border, 21 patients infected with malaria recently participated in a clinical trial.
Disease EradicationGlobal Health PartnershipsMalariaNovartis Social BusinessPatient EducationTropical Diseases -
One man’s fascination with malaria helps fuel the search for new treatments.
Access to HealthcareMalariaNovartis Malaria InitiativeNovartis Social BusinessClinical Trials -
After 40 years of working in information technology, Jim Barrington took a partial retirement from his job as Novartis’ chief information officer and started looking for new ways to apply his skills.
AfricaEmerging TechnologyLocal ImpactMalariaMobile DevicesNovartis Social Business -
Ann Aerts has stared death in the eye. The head of the non-profit Novartis Foundation lost colleagues when she was serving as an emergency medicine physician on a medical mission in a dangerously unstable country.
Emerging TechnologyLocal ImpactMalariaMobile DevicesSocial Commitment -
The disease hobbles families and economies.
Access to HealthcareMalariaNovartis Malaria InitiativeNovartis Social BusinessDrug Development